Krishnan Ramaswamy

  • Citations Per Year
Learn More
We write to comment on a recently published study by Delea et al. in the January 2015 issue of JMCP that evaluated the cost-effectiveness (CE) of sunitinib (SU) versus pazopanib (PAZ) as first-line treatment for metastatic renal cell carcinoma (mRCC) from a U.S. third-party payer perspective.1 This analysis was based on COMPARZ and PISCES, clinical trials(More)
Purpose The purpose is to describe management of adverse events of special interest across tyrosine kinase inhibitors approved for metastatic renal cell carcinoma. Methods We conducted a retrospective chart review in metastatic renal cell carcinoma patients initiating tyrosine kinase inhibitor monotherapy between 15 November 2010 and 15 November 2013, and(More)
■■ Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States We write to comment on a recently published study by Delea et al. in the January 2015 issue of JMCP that evaluated the costeffectiveness (CE) of sunitinib (SU) versus pazopanib (PAZ) as first-line treatment for metastatic renal cell carcinoma (mRCC) from a U.S.(More)
During 1998, the Pennsylvania Department of Health received complaints about hydrogen sulfide odors believed to be associated with mushroom-composting operations in southeastern Pennsylvania. Many residents were concerned about possible illness in students attending an elementary school near the composting operations. In response, the department conducted(More)
  • 1